Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion

Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · Oct 24, 2019

Keywords

ClinConnect Summary

This clinical trial is investigating how a special imaging technique called ultra-wide-field fluorescein angiography can help doctors understand changes in the eye after treatment with a medication known as anti-VEGF. The study focuses on patients who have macular edema, a condition where fluid builds up in the retina due to a blockage in the eye's blood vessels, specifically from retinal vein occlusion (RVO). By looking at changes in blood flow and leakage in the eye, the researchers hope to see if these factors are linked to how well the treatment works.

To join this study, participants need to be at least 18 years old and have recent macular edema caused by RVO that has lasted no longer than four months. They should not have other serious eye conditions or previous treatments that could interfere with the study. If eligible, participants can expect to undergo imaging tests and receive the anti-VEGF treatment while contributing to important research aimed at improving care for others with similar eye conditions. It’s important for potential participants to discuss this opportunity with their eye doctor to see if it’s right for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female aged 18 years or older
• • 2. Macular edema secondary to CRVO,BRVO or HRVO
• • 3. Duration of RVO not more than 4 months
• • 4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) completely resolved (normalization of visual acuity and fundus examination) and who have experienced a recurrence of RVO are also considered naive
• • 5. Patient who agrees to participate in the study and who has given his/her written, informed consent
• Exclusion Criteria:
• • 1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
• • 2. Active or suspected ocular or periocular infection
• • 3. Active severe intraocular inflammation
• • 4. RVO complicated with neovascularization
• • 5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
• • 6. Patient already included in the study for the treatment of the fellow eye
• • 7. Pregnant or breastfeeding woman
• • 8. Lack of effective contraception for women of childbearing age
• • 9. Patient taking part in an interventional study